Study design of the DAS-OLT trial: a randomized controlled trial to evaluate the impact of dexmedetomidine on early allograft dysfunction following liver transplantation
Open Access
- 26 June 2020
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-11
Abstract
Background: Perioperative ischemia/reperfusion (I/R) injury during liver transplantation is strongly associated with early allograft dysfunction (EAD), graft loss, and mortality. Hepatic I/R injury also causes remote damage to other organs including the renal and pulmonary systems. Dexmedetomidine (DEX), a selective α2-adrenoceptor agonist which is used as an adjuvant to general anesthesia, has been shown in preclinical studies to provide organ protection by ameliorating the effects of I/R injury in a range of tissues (including the liver). However, prospective clinical evidence of any potential benefits in improving outcomes in liver transplantation is lacking. This study aimed to verify the hypothesis that the application of dexmedetomidine during the perioperative period of liver transplantation can reduce the incidence of EAD and primary graft non-function (PNF). At the same time, the effects of dexmedetomidine application on perioperative renal function and lung function were studied.Methods: This is a prospective, single-center, randomized, parallel-group study. Two hundred participants (18–65 years) scheduled to undergo liver transplantation under general anesthesia will be included in this study. For participants in the treatment group, a loading dose of DEX will be given after induction of anesthesia (1 μg/kg over 10 min) followed by a continuous infusion (0.5 μg/kg /h) until the end of surgery. For participants in the placebo group, an equal volume loading dose of 0.9% saline will be given after the induction of anesthesia followed by an equal volume continuous infusion until the end of surgery. All other supplements, e.g., opioids, sedatives, and muscle relaxant, will be identical in both arms and administered according to routine clinical practice.Discussion: The present trial will examine whether DEX confers organoprotective effects in the liver, in terms of reducing the incidence of EAD and PNF in orthotopic liver transplantation recipients.Trial registration: ClinicalTrials.govNCT03770130. Registered on 10 December 2018.https://clinicaltrials.gov/ct2/show/NCT03770130Keywords
Funding Information
- School of Medicine, Shanghai Jiao Tong University
- Program of Shanghai Academic Research Leader (2017BR042)
This publication has 44 references indexed in Scilit:
- Dexmedetomidine Inhibits Inflammatory Reaction in Lung Tissues of Septic Rats by Suppressing TLR4/NF-κB PathwayMediators of Inflammation, 2013
- AbstractKidney International Supplements, 2012
- Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in miceCritical Care, 2011
- Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factorsLiver Transplantation, 2010
- Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Rat Kidney: A Histopathologic StudyRenal Failure, 2009
- Acute kidney injury after hepatic ischemia and reperfusion injury in miceLaboratory Investigation, 2008
- A Randomized Controlled Trial on Pharmacological Preconditioning in Liver Surgery Using a Volatile AnestheticAnnals of Surgery, 2008
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006
- The utility of marginal donors in liver transplantationLiver Transplantation, 2003
- EARLY ALLOGRAFT DYSFUNCTION AFTER LIVER TRANSPLANTATIONTransplantation, 1998